LENZ Therapeutics (NASDAQ:LENZ) Stock Crosses Below Fifty Day Moving Average - Here's What Happened

LENZ Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $3.72 and traded as low as $3.43. LENZ Therapeutics shares last traded at $3.50, with a volume of 775,335 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LENZ. Citigroup dropped their price objective on LENZ Therapeutics from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Thursday, November 5th. Piper Sandler lowered their price objective on LENZ Therapeutics from $7.00 to $5.00 and set a "neutral" rating for the company in a research report on Monday, October 19th. Weiss Ratings lowered LENZ Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, September 9th. Zacks Research upgraded LENZ Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 13th. Finally, HC Wainwright reduced their target price on LENZ Therapeutics to $16.00 and set a "buy" rating on the stock in a research report on Friday, October 30th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $14.75.

Check Out Our Latest Analysis on LENZ

LENZ Therapeutics Stock Performance

The business has a fifty day moving average price of $3.72 and a 200 day moving average price of $7.19. The company has a market capitalization of $109.97 million, a PE ratio of -0.78 and a beta of 0.78.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). LENZ Therapeutics had a negative net margin of 1,134.97% and a negative return on equity of 59.56%. The firm had revenue of $3.38 million during the quarter, compared to analyst estimates of $4.20 million. Research analysts forecast that LENZ Therapeutics, Inc. will post -4.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Ra Capital Management, L.P. sold 2,718,684 shares of the firm's stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $3.36, for a total value of $9,134,778.24. Following the transaction, the insider owned 57,559 shares in the company, valued at approximately $193,398.24. This trade represents a 97.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 8.30% of the company's stock.

Institutional Trading of LENZ Therapeutics

Several large investors have recently added to or reduced their stakes in LENZ. Blue Owl Capital Holdings LP purchased a new position in LENZ Therapeutics in the 2nd quarter worth approximately $4,298,000. Bank of America Corp DE boosted its position in LENZ Therapeutics by 377.4% in the 1st quarter. Bank of America Corp DE now owns 547,534 shares of the company's stock valued at $5,010,000 after buying an additional 432,846 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in LENZ Therapeutics in the second quarter valued at about $1,138,000. BlackRock Inc. purchased a new position in shares of LENZ Therapeutics during the 2nd quarter valued at approximately $13,019,000. Finally, Squarepoint Ops LLC raised its holdings in LENZ Therapeutics by 16.0% in the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company's stock valued at $9,924,000 after acquiring an additional 240,597 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

About LENZ Therapeutics

(Get Free Report)

LENZ Therapeutics is a biopharmaceutical company focused on developing treatments for presbyopia, the age-related difficulty focusing on nearby objects. Its lead product, VIZZ (aceclidine ophthalmic solution), is a prescription eye drop approved in the United States for treating presbyopia in adults. VIZZ is designed to improve near vision by constricting the pupil, which can increase depth of focus. The company's work centers on developing and commercializing this topical, non-invasive treatment as an alternative to corrective eyewear for people with presbyopia.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LENZ Therapeutics Right Now?

Before you consider LENZ Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.

While LENZ Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines